Panacea Biotec Pharma Profile
Key Indicators
- Authorised Capital ₹ 60.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 1.00 M
as on 24-10-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1,618.44 Cr
as on 24-10-2024
- Revenue -46.22%
(FY 2023)
- Profit -95.54%
(FY 2023)
- Ebitda -217.12%
(FY 2023)
- Net Worth 12.60%
(FY 2023)
- Total Assets -39.59%
(FY 2023)
About Panacea Biotec Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 60.00 Cr and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹1,618.44 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rajesh Jain, Narotam Juneja, Ankesh Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U24299DL2019PLC347566
- Company No.
347566
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
22 Mar 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Panacea Biotec Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Jain  | Managing Director | 22-Mar-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manjula Upadhyay | Director | 23-Jul-2021 | Current |
| Narotam Juneja | Whole-Time Director | 01-Apr-2022 | Current |
| Ankesh Jain | Whole-Time Director | 22-Mar-2019 | Current |
Financial Performance and Corporate Structure Insights of Panacea Biotec Pharma.
Panacea Biotec Pharma Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 46.22% decrease. The company also saw a substantial fall in profitability, with a 95.54% decrease in profit. The company's net worth Soared by an impressive increase of 12.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Panacea Biotec Pharma?
In 2023, Panacea Biotec Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Panacea Biotec LimitedActive 40 years 10 monthsRajesh Jain, Narotam Juneja and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Feb 2020 | ₹754.44 Cr | Satisfied |
Others Creation Date: 06 Apr 2019 | ₹864.00 Cr | Satisfied |
How Many Employees Work at Panacea Biotec Pharma?
Panacea Biotec Pharma has a workforce of 749 employees as of Mar 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Panacea Biotec Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Panacea Biotec Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
